Insomnia, a prevalent sleep disorder characterized by difficulty in falling or staying asleep, significantly impacts individuals' daily functioning and overall health. Not uncommonly, patients who come to Innerbloom seeking ketamine therapy for their mental health or pain also suffer from sleep disturbances such as insomnia. While we have previously written about this topic, there is limited research regarding the use of ketamine therapy for the treatment of insomnia.
Anecdotally, we have seen some individuals experience significant improvements in subjective sleep quality, with some reporting that they fell asleep faster and felt more restful in the days following ketamine infusions. Certainly, the alleviation of depressive or anxiety symptoms can lead to improvements in sleep. However, there may be other mechanisms or direct effects of ketamine on sleep that have not yet been fully understood.
A recent article in the New England Journal of Medicine by Charles M. Morin, Ph.D., and Daniel J. Buysse, M.D., outlines current strategies for managing insomnia, providing a detailed examination of the disorder, its implications, and effective treatment approaches. Let’s take a closer look at this article and explore how ketamine therapy may play a role in a comprehensive mental health treatment plan.
Insomnia is defined by dissatisfaction with sleep quality or duration, leading to distress or daytime impairment. It is identified when sleep difficulties occur at least three times per week for over three months, without the influence of inadequate sleep opportunities. Insomnia often coexists with other medical or psychiatric conditions, such as depression, anxiety, chronic pain, or other sleep disorders like restless legs syndrome and sleep apnea.
Approximately 10% of adults meet the criteria for insomnia disorder, while another 15-20% experience occasional insomnia symptoms. Women, individuals with mental or medical health issues, and those in middle age or perimenopause are at higher risk. Insomnia can be situational, arising from stress or health issues, or chronic, leading to significant health risks, including major depression, hypertension, Alzheimer’s disease, and work disability.
Diagnosing insomnia involves a thorough history of the patient's sleep patterns, co-occurring conditions, and contributing factors. Tools like sleep diaries and patient-reported assessments help identify insomnia symptoms and monitor treatment progress.
Cognitive Behavioral Therapy for Insomnia (CBT-I): CBT-I is the first-line treatment recommended for persistent insomnia. It combines strategies to modify sleep habits, regulate sleep schedules, reduce arousal from sleep, and address unhelpful beliefs about sleep. CBT-I is typically conducted over four to eight sessions with a mental health therapist, offering substantial improvements in sleep continuity and efficiency.
Medications: Various medications are prescribed to treat insomnia, including benzodiazepine receptor agonists, orexin receptor antagonists, and low-dose antidepressants like Doxepin. These medications can reduce sleep-onset latency and wakefulness after sleep onset but may have side effects like sedation, amnesia, and complex sleep behaviors.
Complementary and Alternative Therapies: Alternative treatments, such as cannabis, cannabidiol (CBD), and melatonin, are used to manage sleep problems, though evidence supporting their efficacy is limited. These treatments may provide relief for some individuals, but often lack robust clinical trial data.
A study published in the Journal of Clinical Psychiatry found that ketamine administration in patients with treatment-resistant depression resulted in significant improvements in sleep quality. This suggests that as ketamine alleviates depressive symptoms, it may concurrently enhance sleep parameters.
“The relationship between sleep disruption and mood disorders is bidirectional, which means sleep impairment may precede mood symptoms or depressed mood can bring about sleep disruption. Moreover, ketamine’s effect on sleep should be taken into consideration from both an antidepressive and antisuicidal perspective.”
Research from the Handbook of Experimental Pharmacology on sleep and wakefulness indicates that ketamine might have direct sleep-modulating effects. The administration of low-dose ketamine elevates the neurotransmitter glutamate in the prefrontal cortex, enhancing synaptic strength and plasticity, which leads to improvements in mood. Furthermore, ketamine increases slow-wave sleep (SWS) and brain-derived neurotrophic factor (BDNF) while altering circadian rhythms, leading to improved sleep in patients with major depressive disorder.
Studies have shown that ketamine can alter sleep architecture. For instance, ketamine has been found to reduce the time it takes to enter REM sleep, which is often disrupted in depressive disorders. This REM sleep modulation might contribute to better overall sleep quality.
While the research is promising, it’s essential to note that ketamine therapy for insomnia is still in its exploratory phase. Here are a few considerations:
Current treatments for insomnia can be effective for some individuals, but several areas of uncertainty persist. These include questions about the long-term efficacy of therapies and medications, the potential development of tolerance, and unique cases of treatment resistance. To address these issues, further research is needed to refine treatment approaches and identify which patients will benefit most from personalized therapies.
Incorporating ketamine therapy into a comprehensive mental health treatment plan could offer additional benefits for individuals struggling with insomnia, especially when it is related to mood disorders. Early research on ketamine therapy is promising, but it is important to approach this option with realistic expectations, recognizing that its use for insomnia is still experimental. Ongoing exploration and research in this area may lead to more effective and holistic approaches for managing this challenging disorder.
About the Author
Dr. Ray Rivas, a former general and trauma surgeon with over a decade of experience utilizing ketamine, became a ketamine therapy specialist to treat mental health and pain after witnessing its profound impact on his hospital trauma patients and his own mental health. As the founder and medical director of Innerbloom Ketamine Therapy in San Luis Obispo, California, Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Disclaimer: All content on this website, including (but not limited to) this statement, news, blog post, article, testimonial, or FAQ is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can do that. Therefore, we cannot be responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to the Terms & Conditions for more information.